HUE027179T2 - Angiogenezis és vasculogenesis modulátor Rspondinek - Google Patents
Angiogenezis és vasculogenesis modulátor Rspondinek Download PDFInfo
- Publication number
- HUE027179T2 HUE027179T2 HUE07819170A HUE07819170A HUE027179T2 HU E027179 T2 HUE027179 T2 HU E027179T2 HU E07819170 A HUE07819170 A HU E07819170A HU E07819170 A HUE07819170 A HU E07819170A HU E027179 T2 HUE027179 T2 HU E027179T2
- Authority
- HU
- Hungary
- Prior art keywords
- rspondin
- angiogenesis
- antibody
- arg
- gly
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Pathology (AREA)
Claims (3)
- Aagiogemzls és vaseufogenests modulátor Rspondinek Szabadalmi igénypontok1, Egy Rspondírfo vagy 3 pokpegtld vagy egy Rspondin2 vagy 3 nukleinsav alkalmazása patológiás állapot kezelésem szolgáló gyógyszer előállításában, ahol a kezelés az angiogenesis és/vagy vasculogenesls elősegítését használja ki
- 3. Az: i, igénypont szerbül alkalmazás sebgyógyulás, szerv regeneráció vagy kiíc-dodes. embrió fejlődés és/vagy repodnkelos folyamat elősegítésére vagy degenerativ folyamatok, különösen vasculodegenerntiv folyamatok, például ischemias folyamatok, példán! kritikus végtag ischemia, agyi ischemia vagy ischemias szívbetegség gátlására,
- 3, Egy Rspondúfo vagy 3: aníagonista alkalmazása angiogenesis és/vagy vaseulogenesis elő-segítésén alapuló, patológiás állapot kezelésére szolgáló gyógyszer előállításában, ahol az antagonists egy aníi-Rspondin 2 vagy anti-Rsponilna amitest vagy egy antiszensz; molekula vagy SÍRNA molekula, 4, Â 3, igénypont szerinti alkalmazás, ahol aRspondio2 vagy 3 antagonists egy aníRRspondm 2 antitest. 5, .A 3. igén> pmu szerinti alkalmazás, ahol a Rspondirfo vagy 3 antagonists egy arfo~Rspoodm 3 antitest, 4 A 4-5. igénypontok bármelyike szerinti alkalmazás, ahol az antitest egy rekombináns pollkfonális, monoklonáils, kimer, humanizált vagy egyláneú antitest vagy íragmense. 1. A 4-6, igénypontok bármehike szerinti alkalmazás:, ahol az antitest egy rnonoklonáhs antitest, S. A 4-4 Igénypontok bármelyike szerinti alkalmazás, aboi az antitest egy humanizált antitest. 9. À 3·»8. igénypontok bármelyike szerinti alkalmazás olya« állapotok megelőzésére vagy kezelésére, ahol a kezelés angiogenezis és/vagy vasculogenesis gátlásával jár, különösen tumor növekedés, elsősorban szilárd tumor növekedés, rheumatoid arthritis, atherosclerosis, stenosis, restenosis, retinopathia, xnaeuiaxis degeoeráelé vagy psoriasis kezelésére.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06022070 | 2006-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE027179T2 true HUE027179T2 (hu) | 2016-10-28 |
Family
ID=39149425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE07819170A HUE027179T2 (hu) | 2006-10-20 | 2007-10-19 | Angiogenezis és vasculogenesis modulátor Rspondinek |
Country Status (13)
Country | Link |
---|---|
US (6) | US8088374B2 (hu) |
EP (2) | EP2081586B2 (hu) |
JP (2) | JP5777281B2 (hu) |
AU (1) | AU2007312538B2 (hu) |
CA (1) | CA2664828A1 (hu) |
DK (1) | DK2081586T4 (hu) |
ES (1) | ES2564794T5 (hu) |
HK (1) | HK1222799A1 (hu) |
HU (1) | HUE027179T2 (hu) |
MX (1) | MX2009003726A (hu) |
PL (1) | PL2081586T5 (hu) |
SI (1) | SI2081586T2 (hu) |
WO (1) | WO2008046649A1 (hu) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2157192T3 (pl) | 2003-10-10 | 2014-01-31 | Deutsches Krebsforsch | Kompozycje do diagnozowania i terapii chorób związanych z nieprawidłową ekspresją futrin (R-spondin) |
US8088374B2 (en) † | 2006-10-20 | 2012-01-03 | Deutsches Krebsforschungszentrum Stiftung Des Offenlichen Rechts | Methods for inhibition of angiogenesis and vasculogenesis via rspondin antagonists |
SI2173379T1 (sl) * | 2007-07-02 | 2015-12-31 | Oncomed Pharmaceuticals, Inc. | Sestavki in postopki za zdravljenje in diagnosticiranje raka |
US8642339B2 (en) | 2009-02-03 | 2014-02-04 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium for epithelial stem cells and organoids comprising the stem cells |
US9752124B2 (en) | 2009-02-03 | 2017-09-05 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium for epithelial stem cells and organoids comprising the stem cells |
EP2412800A1 (en) | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
US20120039912A1 (en) * | 2009-04-15 | 2012-02-16 | Galapagos Sasu | Rspondin-3 inhibition in bone disorders |
EP2977060A1 (en) * | 2009-12-23 | 2016-01-27 | Deutsches Krebsforschungszentrum | Receptors of rspo2 and rspo3 |
AU2013204484B2 (en) * | 2011-07-15 | 2016-05-12 | Oncomed Pharmaceuticals, Inc. | RSPO binding agents and uses thereof |
US8802097B2 (en) | 2011-07-15 | 2014-08-12 | Oncomed Pharmaceuticals, Inc. | Anti-RSPO1 antibodies |
US10010565B2 (en) * | 2011-12-14 | 2018-07-03 | The Board Of Trustees Of The Leland Stanford Junior University | Stimulation of ovarian follicle development and oocyte maturation |
RU2014133069A (ru) | 2012-02-11 | 2016-04-10 | Дженентек, Инк. | Транслокации r-спондина и способы с их использованием |
WO2014012007A2 (en) * | 2012-07-13 | 2014-01-16 | Oncomed Pharmaceuticals, Inc. | Rspo3 binding agents and uses thereof |
BR112016008477A2 (pt) * | 2013-10-18 | 2017-10-03 | Genentech Inc | Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo |
AU2015261380B2 (en) | 2014-05-16 | 2021-04-15 | Koninklijke Nederlandse Akademie Van Wetenschappen | Improved culture method for organoids |
CA2961374A1 (en) | 2014-09-16 | 2016-03-24 | Oncomed Pharmaceuticals, Inc. | Treatment of fibrotic diseases |
GB201421092D0 (en) | 2014-11-27 | 2015-01-14 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium |
GB201421094D0 (en) | 2014-11-27 | 2015-01-14 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium |
WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
GB201603569D0 (en) | 2016-03-01 | 2016-04-13 | Koninklijke Nederlandse Akademie Van Wetenschappen | Improved differentiation method |
EP3443004A1 (en) | 2016-04-14 | 2019-02-20 | H. Hoffnabb-La Roche Ag | Anti-rspo3 antibodies and methods of use |
WO2021080396A1 (ko) * | 2019-10-24 | 2021-04-29 | 가톨릭대학교 산학협력단 | Rspo3 억제제를 포함하는 심장 판막 질환의 예방 또는 치료용 조성물 |
WO2022020544A1 (en) * | 2020-07-23 | 2022-01-27 | The Board Of Trustees Of The University Of Illinois | Method of treating an inflammatory condition |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
AU6765098A (en) | 1997-03-19 | 1998-10-12 | Genetics Institute Inc. | Secreted proteins and polynucleotides encoding them |
WO1998049302A1 (en) | 1997-04-25 | 1998-11-05 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
US20020065394A1 (en) | 1998-03-18 | 2002-05-30 | Kenneth Jacobs | Secreted proteins and polynucleotides encoding them |
US6485972B1 (en) | 1998-10-15 | 2002-11-26 | President And Fellows Of Harvard College | WNT signalling in reproductive organs |
GB9828419D0 (en) | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel compounds |
AU6117000A (en) | 1999-07-26 | 2001-02-13 | Genentech Inc. | Novel polynucleotides and method of use thereof |
WO2001009316A1 (fr) | 1999-07-29 | 2001-02-08 | Helix Research Institute | Nouveaux genes codant la proteine kinase / proteine phosphatase |
US6824973B2 (en) * | 2000-02-03 | 2004-11-30 | Kirin Beer Kabushiki Kaisha | Method of promoting stem cell proliferation or survival by contacting a cell with a stem cell factor-like polypeptide |
US6653448B1 (en) | 2000-03-29 | 2003-11-25 | Curagen Corporation | Wnt-7B-like polypeptides and nucleic acids encoding same |
CA2405104A1 (en) † | 2000-04-05 | 2001-10-18 | Kirin Beer Kabushiki Kaisha | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
US20030022255A1 (en) | 2000-12-22 | 2003-01-30 | Morris David W. | Novel compositions and methods for breast cancer |
EP1356028A2 (en) | 2001-01-31 | 2003-10-29 | Incyte Genomics, Inc. | Protein modification and maintenance molecules |
US20040077048A1 (en) | 2002-01-30 | 2004-04-22 | Warren Bridget A. | Protein modification and maintenance molecules |
US7411052B2 (en) | 2001-03-05 | 2008-08-12 | Nuvelo, Inc. | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
US20030032034A1 (en) * | 2001-03-05 | 2003-02-13 | Tang Y. Tom | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
JP2004533829A (ja) | 2001-04-06 | 2004-11-11 | インサイト・ゲノミックス・インコーポレイテッド | 細胞成長、分化および細胞死関連タンパク質 |
AU2002304249A1 (en) | 2001-06-11 | 2002-12-23 | Kirin Beer Kabushiki Kaisha | Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and dna coding for the same |
US20030022217A1 (en) | 2001-07-02 | 2003-01-30 | Pe Corporation (Ny) | Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
WO2003027230A2 (en) | 2001-08-03 | 2003-04-03 | Incyte Genomics, Inc. | Cell adhesion and extracellular matrix proteins |
EP2228443A1 (en) | 2001-08-30 | 2010-09-15 | ARCA biopharma, Inc. | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
WO2003025142A2 (en) | 2001-09-16 | 2003-03-27 | Nuvelo, Inc. | Novel nucleic acids and secreted polypeptides |
WO2003091280A1 (en) | 2002-04-26 | 2003-11-06 | Kirin Beer Kabushiki Kaisha | Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell or hematopoietic progenitor cell, and dna coding for the same |
AU2003228872A1 (en) | 2002-05-10 | 2003-11-11 | Incyte Corporation | Cell adhesion and extracellular matrix proteins |
WO2004080148A2 (en) | 2002-10-02 | 2004-09-23 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
WO2004099408A1 (ja) | 2003-05-09 | 2004-11-18 | Research Association For Biotechnology | 新規蛋白質およびそれをコードするdna |
WO2005110009A2 (en) * | 2003-07-22 | 2005-11-24 | Immunex Corporation | COMPOSITIONS AND METHODS RELATING TO TSP-30a, b, c AND d |
PL2157192T3 (pl) | 2003-10-10 | 2014-01-31 | Deutsches Krebsforsch | Kompozycje do diagnozowania i terapii chorób związanych z nieprawidłową ekspresją futrin (R-spondin) |
EP2816351A3 (en) | 2004-01-27 | 2015-03-25 | Compugen Ltd. | Methods and systems for annotating biomolecular sequences |
US7439327B2 (en) | 2005-01-18 | 2008-10-21 | Nuvelo, Inc. | Stem cell factor-like proteins and uses thereof |
US20090036369A1 (en) | 2005-07-26 | 2009-02-05 | Kirin Pharma Kabushiki Kaisha | Anti-tumor agents comprising r-spondins |
US7541431B2 (en) | 2005-09-07 | 2009-06-02 | Maine Medical Center | Cristin/R-spondin ligands active in the Wnt signaling pathway and methods, compositions and kits relating thereto |
WO2007100357A2 (en) | 2005-10-07 | 2007-09-07 | Nuvelo, Inc. | Stem cell factor-like protein scfa1 and uses thereof |
JP2008044926A (ja) * | 2006-08-14 | 2008-02-28 | Trustees Of Columbia Univ In The City Of New York | Wnt信号伝達に関係した分泌タンパク質 |
US8088374B2 (en) † | 2006-10-20 | 2012-01-03 | Deutsches Krebsforschungszentrum Stiftung Des Offenlichen Rechts | Methods for inhibition of angiogenesis and vasculogenesis via rspondin antagonists |
SI2173379T1 (sl) | 2007-07-02 | 2015-12-31 | Oncomed Pharmaceuticals, Inc. | Sestavki in postopki za zdravljenje in diagnosticiranje raka |
US8802097B2 (en) | 2011-07-15 | 2014-08-12 | Oncomed Pharmaceuticals, Inc. | Anti-RSPO1 antibodies |
-
2007
- 2007-10-19 US US12/311,921 patent/US8088374B2/en not_active Expired - Fee Related
- 2007-10-19 AU AU2007312538A patent/AU2007312538B2/en not_active Ceased
- 2007-10-19 PL PL07819170T patent/PL2081586T5/pl unknown
- 2007-10-19 MX MX2009003726A patent/MX2009003726A/es active IP Right Grant
- 2007-10-19 WO PCT/EP2007/009105 patent/WO2008046649A1/en active Application Filing
- 2007-10-19 ES ES07819170T patent/ES2564794T5/es active Active
- 2007-10-19 EP EP07819170.7A patent/EP2081586B2/en not_active Not-in-force
- 2007-10-19 CA CA002664828A patent/CA2664828A1/en not_active Abandoned
- 2007-10-19 SI SI200731757T patent/SI2081586T2/sl unknown
- 2007-10-19 EP EP15190671.6A patent/EP2997975A1/en not_active Withdrawn
- 2007-10-19 DK DK07819170.7T patent/DK2081586T4/en active
- 2007-10-19 HU HUE07819170A patent/HUE027179T2/hu unknown
- 2007-10-19 JP JP2009532732A patent/JP5777281B2/ja not_active Expired - Fee Related
-
2011
- 2011-12-01 US US13/309,193 patent/US8580736B2/en not_active Expired - Fee Related
-
2013
- 2013-10-08 US US14/048,225 patent/US8926970B2/en not_active Expired - Fee Related
- 2013-11-29 JP JP2013247353A patent/JP5822897B2/ja not_active Expired - Fee Related
-
2014
- 2014-08-07 US US14/453,692 patent/US9226963B2/en not_active Expired - Fee Related
-
2015
- 2015-09-30 US US14/870,846 patent/US10273276B2/en not_active Expired - Fee Related
-
2016
- 2016-09-21 HK HK16111049.0A patent/HK1222799A1/zh unknown
-
2019
- 2019-03-19 US US16/357,765 patent/US10538563B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10538563B2 (en) | Rspondins as modulators of angiogenesis and vasculogenesis | |
JP2011523551A (ja) | 血管形成の調節の新規ターゲット | |
US20120039912A1 (en) | Rspondin-3 inhibition in bone disorders | |
CA2530582A1 (en) | Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis | |
JP2008237022A (ja) | 非小細胞肺がんの予防・治療剤および診断薬 | |
JP2010131022A (ja) | Dnaマクロアレイプロテオミクスプラットフォームに基づく前立腺癌関連組成物、方法およびキット | |
JP5704722B2 (ja) | 細胞接着阻害剤およびその用途 | |
US7138512B2 (en) | Gene SHINC-2 and diagnostic and therapeutic uses thereof | |
JPH11503620A (ja) | 神経アポトーシス抑制性蛋白質(naip)の使用 | |
JP2007224009A (ja) | 癌の予防・治療剤 | |
WO2001096359A1 (en) | Compositions, methods, and kits relating to resistin-like molecules | |
US20090312245A1 (en) | SRA binding protein | |
JP2001517954A (ja) | Noey2遺伝子組成物およびその使用方法 | |
JP4353697B2 (ja) | がんの予防・治療剤 | |
JPWO2005061704A1 (ja) | 癌の予防・治療剤 | |
JPWO2006101273A1 (ja) | 癌の予防・治療剤 | |
JP2005151826A (ja) | C1qtnf5の用途 |